Answers are grounded in this paper and cite their sources.
Epilepsy is a chronic neurological disorder characterized by recurrent seizures resulting from abnormal and excessive neuronal activity.Although antiseizure medications (ASMs) remain the cornerstone of treatment, approximately one-third of patients develop drug-resistant epilepsy, highlighting the need for alternative therapeutic strategies.Increasing evidence suggests that gut microbiota play an important role in the pathophysiology of epilepsy through bidirectional communication along the gut-brain axis.Beyond cataloguing these associations, this review critically appraises the methodological quality and internal consistency of the existing evidence base, identifies recurring sources of contradiction across studies (sampling design, taxonomic resolution, confounding by diet, and ASM), and proposes an integrative framework in which dysbiosis is treated as a perturbation of a functionally interconnected gutimmune-neural network rather than an isolated biomarker.Experimental and clinical studies have demonstrated alterations in gut microbial composition in patients with epilepsy and in animal models, suggesting a potential disease-associated microbial signature.Moreover, interventions targeting gut microbiota, including ketogenic diet (KD), probiotics, prebiotics, antibiotics, and fecal microbiota transplantation (FMT), have shown promising anticonvulsant effects in preclinical studies, while clinical evidence remains limited and heterogeneous.Among these approaches, the KD currently has the strongest supporting evidence, whereas other microbiota-based therapies remain in the early stages of investigation.Despite substantial progress, causal relationships between alterations in the microbiota and epilepsy are not fully understood, and standardized clinical protocols are lacking.Rather than leaving this open-ended, we reach a graded conclusion: the KD and FMT are currently the only interventions supported by experiments that can distinguish causation from correlation and such evidence is confined to animal models; probiotic, prebiotic, short-chain fatty acid, and antibiotic data remain associative.Therefore, the priority for the field is not further cross-sectional taxonomic profiling-which cannot resolve causality by design-but rather longitudinal pre-diagnosis sampling, function-level multi-omics readouts, and donor-or strain-characterized interventional trials with prespecified microbiota endpoints.Until these are available, microbiota modulation should be positioned as an adjunctive, mechanistically stratified strategy under investigation for drug-resistant epilepsy, rather than as an established therapeutic option.
No takes yet. Share an insight, caveat, or question.
Uğur Aykın (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: